MétaCan
Menu
Back to cohort
Record W2793234123 · doi:10.1002/mdc3.12613

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose‐Escalation Multicenter Study

2018· article· en· W2793234123 on OpenAlexaboutno aff
Joseph Jankovic, Daniel Truong, Atul T. Patel, Allison Brashear, Marian L. Evatt, Roman G. Rubio, Chad K. Oh, Daniel Snyder, Gill Shears, Cynthia Comella

Bibliographic record

VenueMovement Disorders Clinical Practice · 2018
Typearticle
Languageen
FieldMedicine
TopicBotulinum Toxin and Related Neurological Disorders
Canadian institutionsnot available
FundersDystonia CoalitionAllerganSt. Jude MedicalNational Institutes of HealthMerz PharmaceuticalsNational Institute of Neurological Disorders and StrokeUniversity of CambridgeGlenmark PharmaceuticalsIpsenJazz PharmaceuticalsProthenaNeurocrine BiosciencesRevancePsyadon PharmaceuticalsBristol-Myers SquibbAmerican Board of Psychiatry and NeurologyAcorda TherapeuticsH. Lundbeck A/SSunovionAmerican Academy of NeurologyF. Hoffmann-La RocheCivitas TherapeuticsParkinson's FoundationAdamas PharmaceuticalsACADIA PharmaceuticalsCHDI FoundationMedtronicSanofiPfizerParkinson's Disease FoundationUS WorldMedsTeva Pharmaceutical IndustriesKyowa Kirin Pharmaceutical DevelopmentU.S. Department of Veterans Affairs
KeywordsCervical dystoniaMedicineDystoniaMulticenter studyAnesthesiaInternal medicinePsychiatry

Abstract

fetched live from OpenAlex

BACKGROUND: Injectable daxibotulinumtoxinA (an investigational botulinum toxin, RT002) may offer a more prolonged duration of response-and therefore less frequent dosing-than onabotulinumtoxinA. OBJECTIVES: To perform a phase 2, open-label, dose-escalation study to assess the efficacy and safety of daxibotulinumtoxinA in cervical dystonia. METHODS: 13; https://clinicaltrials.gov identifier NCT02706795). RESULTS: Overall, 33/37 enrollees completed the trial. DaxibotulinumtoxinA was associated with mean reductions in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score of 16.8 (38%) at week 4, 21.3 (50%) at week 6, and 12.8 (30%) at week 24. The proportion of subjects who were responders (achieved ≥ 20% reduction in TWSTRS-Total score) was 94% at week 6 and 68% at week 24. The median duration of response (time until > 20% of the improvement in TWSTRS-Total score achieved at week 4 was no longer retained or re-treatment was needed) was 25.3 weeks (95% CI, 20.14-26.14 weeks). There were no serious adverse events and there was no apparent dose-related increase in the incidence of adverse events. The most common treatment-related adverse events were dysphagia (14%) and injection site erythema (8%). CONCLUSIONS: Preliminary assessments suggest that injectable daxibotulinumtoxinA at doses up to 450 U is well tolerated and may offer prolonged efficacy in the treatment of cervical dystonia. Further studies involving larger numbers of patients are now warranted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.417
Teacher spread0.374 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations56
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueMovement Disorders Clinical PracticeSame topicBotulinum Toxin and Related Neurological DisordersFrench-language works237,207